Addison's Disease Global Market Report 2025

The addison's disease market size has grown rapidly in recent years. It will grow from $2.05 billion in 2024 to $2.25 billion in 2025 at a compound annual growth rate (CAGR) of 10%. The growth during the historic period can be attributed to the increasing global incidence of Addison's disease, greater awareness of adrenal insufficiency, rising healthcare expenditure, a higher prevalence of autoimmune diseases, and a growing geriatric population.

The addison's disease market size is expected to see strong growth in the next few years. It will grow to $3.26 billion in 2029 at a compound annual growth rate (CAGR) of 9.7%. The growth during the forecast period can be driven by the rising demand for advanced therapeutics, an increased focus on early diagnosis, a growing prevalence of congenital adrenal hyperplasia cases, the expansion of telemedicine services, and a higher incidence of adrenal tuberculosis. Key trends in this period include advancements in laboratory testing methodologies, innovations in hormone replacement therapies, improvements in imaging technologies, the development of long-acting injectable formulations, and the integration of artificial intelligence in diagnostic tools.

The rising prevalence of autoimmune diseases is expected to drive the growth of the Addison’s disease market. Autoimmune diseases occur when the immune system mistakenly attacks the body's healthy tissues, leading to inflammation and damage. Factors such as genetic predisposition, environmental influences such as pollutants and dietary changes, and lifestyle aspects such as stress and lack of physical activity contribute to the increasing occurrence of autoimmune diseases. The growing prevalence of these conditions also raises the likelihood of co-occurrence with Addison’s disease, as many patients develop multiple autoimmune disorders. For example, in November 2024, Versorgungsatlas.de, a Germany-based organization, reported that in 2022, among 73,241,305 insured individuals, 6,304,340 were diagnosed with at least one autoimmune disease, resulting in a raw prevalence rate of 8.61%, higher than previous estimates of 3% to 9%. As a result, the increasing prevalence of autoimmune diseases is fueling the expansion of the Addison’s disease market.

Leading companies in the Addison’s disease market are focusing on innovative approaches such as regenerative therapies to enhance treatment options, improve patient outcomes, and potentially reduce lifelong dependence on hormone replacement therapies by stimulating the body's natural adrenal function. Regenerative therapies involve medical techniques aimed at replacing or regenerating human cells, tissues, or organs to restore normal function and promote healing in cases of disease, injury, or degeneration. For instance, in July 2024, Eton Pharmaceuticals, Inc., a US-based pharmaceutical company specializing in treatments for rare diseases, announced that the FDA had accepted its New Drug Application (NDA) for ET-400, a proprietary hydrocortisone oral solution. ET-400 offers improved storage and transport benefits compared to formulations requiring refrigeration. Additionally, its liquid format is designed to meet the needs of young patients who may struggle with swallowing tablets, allowing for more precise dosing.

In November 2022, Neurocrine Biosciences Inc., a US-based biotech company, acquired Diurnal Group plc for $56.5 million. This acquisition strengthens Neurocrine Biosciences’ portfolio in rare endocrine disorders by incorporating Diurnal Group’s expertise in adrenal hormone therapies. Diurnal Group plc, a UK-based biotech company, specializes in developing treatments for adrenal insufficiency, including Addison’s disease.

Major players in the addison's disease market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc., Bayer AG, Bristol-Myers Squibb Company, Novartis AG, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Amgen Inc., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Sandoz, Ipsen S.A., Neurocrine Biosciences Inc., Recipharm AB, Accord Healthcare, Eton Pharmaceuticals, DuoCort Pharma, Diurnal Group plc, and Roxane Laboratories Inc.

North America was the largest region in the addison's disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in addison's disease report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the addison's disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Addison's disease is a rare condition in which the adrenal glands produce insufficient cortisol and aldosterone due to damage, often caused by an autoimmune response. Symptoms include fatigue, muscle weakness, weight loss, low mood, and skin changes. Lifelong hormone replacement therapy is essential to manage the condition and prevent severe complications such as adrenal crisis.

The primary types of Addison's disease include primary, secondary, and tertiary adrenal insufficiency. Primary adrenal insufficiency occurs when the adrenal glands fail to produce adequate cortisol and, in some cases, aldosterone due to damage or dysfunction. Management involves various drug classes, such as oral corticosteroids, hydrocortisone, fludrocortisone, and corticosteroid injections. Diagnosis typically involves laboratory and imaging tests to assess adrenal gland function. Patient care is facilitated by several end-users, including hospitals, clinics, diagnostic laboratories, and other healthcare providers.

The addison's disease market research report is one of a series of new reports that provides addison's disease market statistics, including the addison's disease industry global market size, regional shares, competitors with the addison's disease market share, detailed addison's disease market segments, market trends, and opportunities, and any further data you may need to thrive in the addison's disease industry. This addison's disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The addison's disease market consists of revenues earned by entities by providing services such as diagnostic services, treatment services, and surgical services. The market value includes the value of related goods sold by the service provider or included within the service offering. The addison's disease market also includes sales of adjunct therapies, diagnostic tools, adrenocorticotropic hormone (ACTH) stimulation test kits, blood cortisol, and ACTH testing kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.